Hot Flashes and Night Sweats – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Hot Flashes and Night Sweats Market Outlook

Thelansis’s “Hot Flashes and Night Sweats Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hot Flashes and Night Sweats   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hot Flashes and Night Sweats Overview

Hot Flashes and Night Sweats are significant symptoms that occur in most women across the globe. A woman with Vasomotor Symptoms experiences much heat accompanied by sweating and flushing, especially around the head, neck, chest, and upper back region. These are the menopausal symptoms for which women seek treatment most often during menopause. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones. 60-80% of women experience VMS during the menopausal transition, with prevalence rates varying by racial/ethnic group. One of the well-known symptoms of menopause is the occurrence of hot flashes, which occur in >75% of menopausal women. Hot flashes are often described as episodic sensations of heat, intense sweating, and flushing affecting the face and chest, often accompanied by palpitations and anxiety. Each episode lasts 3–10 minutes, and attacks can recur with varying frequency. Some women encounter hot flashes hourly or daily, whereas, for others, they may occur occasionally. The age at onset of hot flashes is hypothesized to be involving pathology of the thermoregulatory nucleus that is crucial in controlling the homeostatic condition and, therefore, the core body temperature. The thermoregulatory nucleus maintains the core temperature within the intervals of physiological needs, termed a thermoregulatory zone.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Hot Flashes and Night Sweats  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034